This inventor holds 3 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignee: Lek Pharmaceuticals D.d.. Active years: 2014-2018.
Location History:
- Ljubljana, SI (2014)
- Vrhnika, SI (2015 - 2018)
Company Filing History:
Years Active: 2014-2018
Title: Mateja Burjak: Innovating Pharmaceutical Dosage Forms for Enhanced Stability
Introduction:
In the world of pharmaceuticals, innovative minds are constantly working to develop new solutions that improve drug stability and efficacy. Mateja Burjak, a skilled inventor and researcher from Vrhnika, Slovenia, is one such individual who has made significant contributions to the field. With multiple patents to his name, Mateja Burjak's work at Lek Pharmaceuticals D.d. has focused on developing coated particles and pharmaceutical dosage forms that offer enhanced stability and protection against environmental influences.
Latest Patents:
Burjak's recent patents revolve around coated particles and pharmaceutical dosage forms designed to protect sensitive active substances from environmental factors such as oxidation and humidity. These inventions aim to provide a stable platform for drug delivery, ensuring that medications remain effective throughout their shelf life. The innovative coatings developed by Burjak offer an important solution for maintaining the potency and reliability of pharmaceutical products.
Career Highlights:
Mateja Burjak's career at Lek Pharmaceuticals D.d. has been marked by his commitment to innovation in drug formulation. His expertise in the field of coatings and pharmaceutical dosage forms has led to the development of groundbreaking solutions. By combining his scientific knowledge with a keen understanding of market needs, Burjak has helped advance pharmaceutical technology and improve patient outcomes through his inventions.
Collaborations:
Successful innovation often relies on the collaborative efforts of talented individuals. Mateja Burjak has had the privilege of working alongside esteemed colleagues, including Vlasta Humar and Rok Grahek. Together, they have contributed to the development of cutting-edge pharmaceutical technologies and fostered an environment of scientific excellence. Their collaborative efforts have paved the way for novel approaches in drug delivery and dosage form design.
Conclusion:
Mateja Burjak's intellectual contributions to the field of pharmaceuticals cannot be overstated. His dedication to finding novel solutions for drug stability and protection from environmental influences has led to several patented inventions. Through his work at Lek Pharmaceuticals D.d. and collaborations with fellow researchers, Burjak continues to push the boundaries of pharmaceutical innovation. As the industry progresses, his contributions will undoubtedly play a significant role in advancing drug development and improving patient care.